| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 7136- | GI, | [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2 |
| - | vitro+vivo, | NSCLC, | H1650 |
| 7139- | GI, | 6-Shogaol Exhibits a Promoting Effect with Tax via Binding HSP60 in Non-Small-Cell Lung Cancer |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U251 |
| 1116- | GI, | 6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT116 |
| 7261- | Gink, | Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway |
| - | in-vitro, | RCC, | 786-O |
| 7245- | Gink, | Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | MCF10 |
| 7247- | Gink, | Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT474 | - | vitro+vivo, | BC, | MCF7 |
| 7264- | Gink, | Anti-tumor effect of ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis |
| - | vitro+vivo, | HCC, | HepG2 | - | NA, | HCC, | SK-HEP-1 |
| 7265- | Gink, | Ginkgetin targets GRP78 to induce dual pathways of ER stress and immune activation in osteosarcoma |
| - | vitro+vivo, | OS, | NA |
| 7266- | Gink, | Ginkgo biloba derivative ginkgetin inhibits breast cancer growth by regulating the miRNA-122-5p/GALNT10 axis |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-453 | - | in-vitro, | BC, | MCF7 |
| 7258- | Gink, | Ginkgetin inhibits the growth of DU−145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity |
| - | vitro+vivo, | Pca, | DU145 | - | in-vitro, | CRC, | HCT116 |
| 7257- | Gink, | Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through inhibition of STAT3 and activation of caspase-3/9 |
| - | in-vitro, | OS, | NA |
| 7297- | GlaB, | H-NMR metabolomics reveals the Glabrescione B exacerbation of glycolytic metabolism beside the cell growth inhibitory effect in glioma |
| - | vitro+vivo, | GBM, | NA |
| 7302- | GlaB, | Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma |
| - | vitro+vivo, | MB, | NA |
| 32- | GlaB, | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors |
| - | in-vivo, | MB, | NA |
| 7315- | Gos, | Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells |
| - | vitro+vivo, | CRC, | HT29 | - | in-vitro, | CRC, | COLO205 |
| 7312- | Gos, | A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 7309- | Gos, | Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa |
| - | vitro+vivo, | Pca, | PC3 |
| 7337- | Gra, | Synergistic interactions among flavonoids and acetogenins in Graviola (Annona muricata) leaves confer protection against prostate cancer |
| - | in-vitro, | Pca, | NA |
| 7335- | Gra, | Effect of Annona muricata (Soursop) on Patients with Cancer: A Systematic Review |
| - | Review, | Var, | NA |
| - | in-vitro, | NMSC, | A431 | - | in-vitro, | NMSC, | UW-BCC1 | - | in-vitro, | Nor, | NHEKn |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | CCD841 |
| 855- | Gra, | Antiproliferative activity of ionic liquid-graviola fruit extract against human breast cancer (MCF-7) cell lines using flow cytometry techniques |
| - | in-vitro, | BC, | MCF7 |
| 1292- | GSE, | EGCG, | Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT8 |
| 7323- | GSE, | Grape seed procyanidin extract against lung cancer: the role of microrna-106b, bioavailability, and bioactivity |
| - | vitro+vivo, | Lung, | NA |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 2516- | H2, | Hydrogen Gas in Cancer Treatment |
| - | Review, | Var, | NA |
| 3770- | H2, | Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 292- | HCA, | Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway |
| - | in-vitro, | AML, | K562 |
| 293- | HCA, | Tam, | Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase |
| - | in-vitro, | BC, | MCF7 |
| 1625- | HCA, | In S. cerevisiae hydroxycitric acid antagonizes chronological aging and apoptosis regardless of citrate lyase |
| - | Review, | Nor, | NA |
| 2400- | HCAs, | The Mixture of Ferulic Acid and P-Coumaric Acid Suppresses Colorectal Cancer through lncRNA 495810/PKM2 Mediated Aerobic Glycolysis |
| - | in-vitro, | CRC, | NA | - | in-vivo, | CRC, | NA |
| 2407- | HCAs, | 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 7369- | HibSad, | Components in aqueous Hibiscus rosa-sinensis flower extract inhibit in vitro melanoma cell growth |
| - | in-vitro, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | LA25 |
| 7467- | HNK, | Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation |
| - | vitro+vivo, | Oral, | NA |
| 7463- | HNK, | Honokiol Inhibits Colorectal Cancer Cell Growth: Involvement of Hsp27 as a Molecular Target |
| - | in-vitro, | CRC, | NA |
| 7461- | HNK, | Honokiol: a potent chemotherapy candidate for human colorectal carcinoma |
| - | vitro+vivo, | CRC, | RKO |
| 1021- | HNK, | Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer |
| - | in-vivo, | Lung, | NA |
| 1120- | HNK, | Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling |
| - | vitro+vivo, | RCC, | NA |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| 4688- | HNK, | Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling |
| - | vitro+vivo, | RCC, | A498 |
| 7527- | HT, | Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation |
| - | vitro+vivo, | NA, | HT29 | - | in-vitro, | NA, | Caco-2 |
| 601- | HT, | Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells |
| - | in-vivo, | NA, | HT-29 |
| 4642- | HT, | Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways |
| - | in-vitro, | HCC, | HepG2 | - | NA, | NA, | Hep3B | - | NA, | NA, | SK-HEP-1 |
| 7547- | HYP, | Hyperoside suppresses NSCLC progression by inducing ATG13-mediated autophagy and apoptosis |
| - | vitro+vivo, | NSCLC, | NA |
| 7551- | HYP, | Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1 |
| - | vitro+vivo, | NSCLC, | NA |
| 7556- | HYP, | Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo |
| - | vitro+vivo, | PC, | NA |
| 7560- | HYP, | Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 7596- | I3C, | Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent |
| - | in-vitro, | BC, | NA |
| 7608- | I3C, | Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:323 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid